By The Wondr Health Team Obesity and weight-related chronic conditions are one of the most pressing challenges in the modern workplace
Indeed, this type of inhibitory mechanism was described for blocking the interaction between another cytokine receptor, the interleukin-2 receptor, and its ligand
Olave FA, Aguayo FI, Roman-Albasini L, Corrales WA, Silva JP, Gonzalez PI, et al
GIP Glucose-Dependent Insulinotropic Polypeptide Incretin K (K-cell) (Duodenum) GLP-1 GLP-1 receptor GIP receptor 2 GLP-1 2 GLP-1 (Glucagon-like Peptide-1) GIP (Glucose-dependent Insulinotropic Polypeptide) Mounjaro (Tirzepatide) GLP-1 GIP Mounjaro (Tirzepatide) GLP-1 GIP Dual GIP/GLP-1 Receptor Agonist : : SURMOUNT-1 tirzepatide semaglutide SURMOUNT-5 tirzepatide semaglutide 47% (Rubino et al., 2026, NEJM) : 3 (Triple agonist : GLP-1, GIP, Glucagon) Retatrutide 3 FAQ GLP-1 GIP GLP-1/GIP